Boan Biotech Highlights Clinical Updates for BA6101 (biosimilar, Prolia) and BA1102 (biosimilar, Xgeva) to Treat Various Indications

Shots: The company has completed patient enrolment in P-III trial which evaluates the safety, efficacy, PK & immunogenicity of BA6101 & BA1102 vs reference drugs (Prolia & Xgeva) for the treatment of various indication across Europe, United States & Japan Boan also conducted a meeting in Germany to highlight the PK results from the…

ByDipanshu DixitJanuary 15, 2024

TOP 20

Top 20 Monoclonal Antibodies Based on 2022 Total Revenue

Shots: Monoclonal antibodies are transforming therapeutics through their highly efficient targeting mechanisms. There is a wide range of uses for monoclonal antibodies, including diagnosis, therapy, and research In 2021, the monoclonal antibody therapy market size was valued at $178.5B and is envisioned to reach $451.89B by 2028, displaying a CAGR of 14.1%. Humira was the…

ByPrince GiriSeptember 26, 2023

Boan Biotech Highlights Clinical Updates for BA6101 (biosimilar, Prolia) and BA1102 (biosimilar, Xgeva) to Treat Various Indications

Top 20 Monoclonal Antibodies Based on 2022 Total Revenue

Contact US

OUR INFORMATION

FOLLW US

Boan Biotech Highlights Clinical Updates for BA6101 (biosimilar, Prolia) and BA1102 (biosimilar, Xgeva) to Treat Various Indications

Top 20 Monoclonal Antibodies Based on 2022 Total Revenue

FOLLW US

Sign Up to Our Newsletter